August 04, 2017
In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
Case Number:
2:17-md-02785
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Sidley Austin
- Squitieri & Fearon
- Law Offices of Ursula Taylor
- Matthew G. Miller PC
- Spencer Fane
- Berman Tabacco
- Foulston Siefkin
- Sharp Law LLP
- Parker Waichman
- Burns Charest
- Siegfried & Jensen
- Spragens Law
- Saiber LLC
- Lockridge Grindal
- Pritzker Levine
- Berkowitz Oliver
- Hogan Lovells
- Joseph Saveri Law Firm
- Barton & Burrows
- Kaufman & Canoles
- Beasley Allen
- DiCello Levitt
- Goldman Scarlato
- Robbins Russell
- Kramer Levin
- Perkins Coie
- Yarmuth LLP
- Pallas Partners
- Lanier Law Firm
- Groom Law Group
- Hagens Berman
- Lightfoot Franklin
- Hinkle Law Firm
- Keller Rohrback
- Robins Kaplan
- Carella Byrne
- Marion's Inn
- Goodwin Procter
- Strategic Health Law
- Reed Smith
- Dollar Burns
- Holland & Knight
- Butler Prather
- King & Spalding
- Barnow & Associates
- Gustafson Gluek
- Boies Schiller
- Fredrikson & Byron
- Bradford & Wilson
- Williams & Connolly
- Horn Aylward
- Bush Seyferth
- Wagstaff & Cartmell
- Gibson Dunn
- Mehri & Skalet
- Blood Hurst
- Shook Hardy
- Lowey Dannenberg
- Steven Williams Law
- Wilson Sonsini
- Levi & Korsinsky
- Gibbons PC
- Weil Gotshal
- Robbins Geller
- Ali & Lockwood
- Clark Hill
- Lathrop GPM
- GM Law PC
- DLA Piper
- Foley & Lardner
- Baron & Budd
- Latham & Watkins
- Mayer Brown
- White & Case
- Willkie Farr
Companies
- Amerigroup Corp.
- Change Healthcare Inc.
- MedImpact Healthcare Systems Inc.
- CVS Health Corp.
- Meridian Medical Technologies Inc.
- Coventry Health Care Inc.
- Express Scripts Holding Co.
- The Segal Co. Inc.
- Humana Inc.
- Blue Cross Blue Shield Association
- Viatris Inc.
- UnitedHealth Group Inc.
- Aetna Inc.
- OptumRx Inc.
- Centene Corp.
- King Pharmaceuticals Inc.
- Optum Inc.
- Sanofi
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
March 14, 2022
Judge OKs $264M Deal Ending Mylan EpiPen Price-Hike Suit
A Kansas federal court has preliminarily approved a $264 million deal that would end claims that Mylan colluded with Pfizer Inc. to obstruct generic versions of the EpiPen, the emergency drug used to treat severe allergic reactions, from entering the market.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login